1. Eschweiler, Simon, Wang, Alice, Ramírez-Suástegui, Ciro, Ottensmeier, Christian H, Vijayanand, Pandurangan. 2023. JAML immunotherapy targets recently activated tumor-infiltrating CD8+ T cells. In Cell reports, 42, 112040. doi:10.1016/j.celrep.2023.112040. https://pubmed.ncbi.nlm.nih.gov/36701231/
2. Hao, Zhixing, Xin, Zhongwei, Chen, Yongyuan, Wu, Dang, Wu, Pin. 2024. JAML promotes the antitumor role of tumor-resident CD8+ T cells by facilitating their innate-like function in human lung cancer. In Cancer letters, 590, 216839. doi:10.1016/j.canlet.2024.216839. https://pubmed.ncbi.nlm.nih.gov/38570084/
3. Fang, Yuying, Liu, Yanan, Dong, Zhilin, Yang, Jianmin, Sun, Meili. 2024. JAML overexpressed in colorectal cancer promotes tumour proliferation by activating the PI3K-AKT-mTOR signalling pathway. In Scientific reports, 14, 24514. doi:10.1038/s41598-024-75180-z. https://pubmed.ncbi.nlm.nih.gov/39424882/
4. McGraw, Joseph M, Thelen, Flavian, Hampton, Eric N, Havran, Wendy L, Witherden, Deborah A. 2021. JAML promotes CD8 and γδ T cell antitumor immunity and is a novel target for cancer immunotherapy. In The Journal of experimental medicine, 218, . doi:10.1084/jem.20202644. https://pubmed.ncbi.nlm.nih.gov/34427588/
5. Fang, Likui, Yu, Wenfeng, Yu, Guocan, Zhong, Fangming, Ye, Bo. 2022. Junctional Adhesion Molecule-Like Protein (JAML) Is Correlated with Prognosis and Immune Infiltrates in Lung Adenocarcinoma. In Medical science monitor : international medical journal of experimental and clinical research, 28, e933503. doi:10.12659/MSM.933503. https://pubmed.ncbi.nlm.nih.gov/35034089/
智鼠故事 
